

## **Press Release Archives**

**November 20, 2003**

### **Press reports regarding M/s. Indusind Bank Ltd.**

The press had reports that Indusind Bank Limited is likely to acquire Centurion Bank and a non-banking finance company. There were also reports of merger of a group company - Ashok Leyland Finance & Leasing with the bank.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Indusind Bank Limited has vide its letter inter-alia stated, "As regards the matter of acquisition of Centurion bank, we wish to state that there is no such development in this regard. As regards talks of merger of Ashok Leyland Finance with the Bank, we reiterate our position that our Bank is in the process of increasing its share of retail business, which is part of the normal business activities of a banking company. The logical route is to explore the feasibility of expanding our reach by utilising the strengths and facilities of existing players in the system. As part of this plan, our Bank is pursuing options with various NBFCs, one among them being Ashok Leyland Finance. We further clarify that no formal initiative has yet been taken in this direction with any of the NBFCs, which includes Ashok Leyland Finance. We shall advise the Stock Exchange, as soon as any such development in this regard takes place."

[Top](#)

### **Press reports regarding M/s. Tasc Pharmaceuticals Ltd.**

The press had reports that Tasc Pharmaceuticals Limited has decided to expand and upgrade its research & manufacturing facilities with an additional investment of Rs. 10 crore and is awaiting a few outsourcing contracts.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Tasc Pharmaceuticals Limited has vide its letter inter-alia stated, "The Company has 2 facilities spread over around 20 acres of land within MIDC (D-10 & A-88), Kurkumbh. The installed capacity of the Company at D-10 unit is around 600 TPA for Ciprofloxacin/Enrofloxacin and at A-88 unit is 360 TPA for Ranitidine and 180 TPA for other mixed drugs. With such a huge establishment, the Company has additional capacities, which can be utilized for contract manufacturing. The Company is also in the process of upgrading itself for achieving the standards for COS/DMF for its products. All this will call for further investment of Rs. 10 crore appx, for upgrading its research and manufacturing facilities for outsourcing contracts and ensure higher acceptability of the Company's products in the international markets."

[Top](#)

### **Press reports regarding M/s. Bombay Burmah Trading Corporation Ltd.**

The press had reports that the Wadia group plans to divest some businesses of Bombay Burmah Trading Corporation Limited as part of a restructuring exercise.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Reply is awaited from Bombay Burmah Trading Corporation Limited.

[Top](#)

### **The Exchange has successfully completed its 939th Normal Settlement**

The Exchange has successfully completed its 939th Normal Settlement (Rolling T+2 following SEBI directive) since inception i.e., Settlement Number N – 2003223 on November 20, 2003. The settlement statistics are as follows:

Particulars	Values
	N - 2003223
Total traded quantity (lakhs)	2851.12
Total traded value (Rs. In Crores)	4481.91
Total value of the settlement (Securities) (Rs. In Crores)	771.12
Total value of the settlement (Funds) (Rs. In Crores)	204.70
Shortages for the settlement	0.57%
% of Delivery ( No. of shares delivered / No. of shares traded )	22.05%

Retail Debt Market has completed its 213th settlement, details of which are as follows :

Settlement No.	Traded Value	Settlement Value	
		Securities	Funds
2003223	Nil	Nil	Nil

[Top](#)